ENTITY

Legochem Biosciences (141080 KS)

41
Analysis
Health Care • South Korea
LegoChem Biosciences, Inc. (LCB) is a researched-based biotechnology company that discovers, develops, and commercializs of medicines. The Company utilizes chemistry to make biologics more targeted and potent for patients with diseases of highly unmet medical needs. The Company focuses on therapy within antibiotics, anti-coagulants, oncology, antibody and protein-drug conjugate.
more
•19 Jun 2026 07:53•Broker

[2H26 Outlook] Pharma/BiotechCatalysts for a biotech rebound

Biotech stocks performed well early this year, driven by optimism surrounding the government's KOSDAQ 3,000 target and supportive fund flows...

Logo
119 Views
Share
•07 Jun 2026 08:30

APAC Healthcare Weekly (June 7) – CSPC Pharma, Innovent, Shionogi, Hanmi Pharm, SK Bioscience, Lupin

Innovent submitted NDA for oncology drug. Shionogi got FDA approval for Xocova. Hanmi Pharm signed $1.2B outlicensing deal with Lilly. SK...

Logo
167 Views
Share
•01 Mar 2026 08:30

APAC Healthcare Weekly (March 1) – CStone, HBM, Astellas, Bora Pharma, Lupin, Zydus Lifesciences

CStone’s sugemalimab got label expansion in UK. HBM Holdings entered exclusive license agreement with Solstice Oncology. Astellas Pharma and Vir...

Logo
655 Views
Share
•15 Feb 2026 08:30

APAC Healthcare Weekly (February 15)–Innovent Bio, InSilico, Eisai, Takeda, Alteogen, Pharmaessentia

Few Chinese biotech companies entered drug development collaborations. Eisai’s Leqembi autoinjector gets priority review in China. FDA will likely...

Logo
451 Views
Share
•11 Jan 2026 08:30

APAC Healthcare Weekly (January 11) – Hengrui, Hansoh, InSilico Medicine, Takeda, Hanmi Pharm

Hegrui got nod for new drug and Hansoh’s Ameile secured additional indication in China. InSilico entered $888M R&D collaboration. Takeda filed for...

Logo
338 Views
Share
x